MedTrace Logo

Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia

NCT01386918 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2012-01-06

No results posted yet for this study

Summary

Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise. The majority of studies have examined the effect of low frequency left-sided stimulation (LFL) (i.e., 1 Hz) to the temporal parietal cortex (TPC). Priming stimulation (6 Hz) prior to LFL stimulation (hereby simply referred to as priming) has been shown to enhance the neurophysiological effects of LFL rTMS alone and, as such, may lead to greater attenuation of AH. Therefore, this study evaluated the efficacy of priming rTMS and LFL rTMS, compared to sham, applied to the TPC in patients with schizophrenia experiencing refractory auditory hallucinations (AH).

Conditions

  • Refractory Schizophrenia

Interventions

DEVICE

repetitive Transcranial Magnetic Stimulation

The treatment involves the administration of a magnetic field applied to a specific area of the brain.

Sponsors & Collaborators

  • Ontario Mental Health Foundation

    collaborator OTHER_GOV

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Z J Daskalakis, MD · Centre for Addiction and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01386918 on ClinicalTrials.gov